抗gp210抗体对原发性胆汁性肝硬化的价值

目的评估抗gp210抗体对原发性胆汁性肝硬化（PBC）患者诊断、治疗和预后的意义。方法分析83例PBC患者的资料,随访观察临床表现、肝功能、PBC相关自身抗体和熊去氧胆酸（UDCA）治疗反应。结果抗gp210阳性组清蛋白平均水平明显低于阴性组（P〈0.05）,总胆红素（TBIL）平均水平高于阴性组,差异无统计学意义。随访阳性组肝衰竭发生率高于阴性组（P〈0.05）;UDCA治疗1年患者谷丙转氨酶（ALT）、碱性磷酸酶（ALP）、γ-谷氨酰转肽酶（γ-GT）平均水平明显低于初诊（P〈0.05）,抗gp210阳性患者生化指标间差异无统计学意义。结论抗gp210可作为预后指标;UDCA能有效改善患者的生化指标,长期应用延缓疾病进展。

The value of anti-gp210 antibodies in patients with primary biliary cirrhosis

Objective To evaluate the clinical significance of anti-gp210 antibodies for diagnosing and treating patients with Primary brimary cirrhosis(PBC).Methods A total of 83 patients with PBC were studied.The clinical manifestations,liver function tests,PBC associated autoantibodies and treatment rsponse with UDCA were followed for one year.Results Compared with anti-gp210 antibody negative group,the mean level of serum albumin was significantly lower that in anti-gp210 antibody positive group,t the hepatic failure rate was significantly higher in anti-gp210 antibodies positive group than that in anti-gp210 antibodies negative group(P<0.05).Mean levels of serum alanine transarninase(ALT)、alkaline phosphatase(ALP)、glutamyltranspeptidase(γ-GT) were significantly decreased after one year treatment with UDCA but not statistically significant in anti-gp210 positive patients.Conclusion Anti-gp210 antibody can make a prognostic indicator;UDCA can improve biochemical indicators of patients effectively,Long-term application can postpone progress of PBC.